Blood Res.
2015 Dec;50(4):254-256. 10.5045/br.2015.50.4.254.
Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. gmlrud16.kim@samsung.com
- KMID: 2133761
- DOI: http://doi.org/10.5045/br.2015.50.4.254
Abstract
- No abstract available.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Brentuximab vedotin: clinical updates and practical guidance
- CD30＋ Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin
- A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
- Recent updates on extranodal NK/T-cell lymphoma
- A Case of Primary Cutaneous CD30(Ki-1)-positive Large Cell Lymphoma Showing Repetitive Spontaneous Regression and Recurrences
